Carriers of rare damaging
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
16 Aug 2023
16 Aug 2023
Historique:
pubmed:
30
8
2023
medline:
30
8
2023
entrez:
30
8
2023
Statut:
epublish
Résumé
The CCL2/CCR2 axis governs monocyte trafficking and recruitment to atherosclerotic lesions. Human genetic analyses and population-based studies support an association between circulating CCL2 levels and atherosclerosis. Still, it remains unknown whether pharmacological targeting of CCR2, the main CCL2 receptor, would provide protection against human atherosclerotic disease. In whole-exome sequencing data from 454,775 UK Biobank participants (40-69 years), we identified predicted loss-of-function (LoF) or damaging missense (REVEL score >0.5) variants within the A total of 45 predicted LoF or damaging missense variants were identified in the Heterozygous carriers of damaging
Sections du résumé
Background
UNASSIGNED
The CCL2/CCR2 axis governs monocyte trafficking and recruitment to atherosclerotic lesions. Human genetic analyses and population-based studies support an association between circulating CCL2 levels and atherosclerosis. Still, it remains unknown whether pharmacological targeting of CCR2, the main CCL2 receptor, would provide protection against human atherosclerotic disease.
Methods
UNASSIGNED
In whole-exome sequencing data from 454,775 UK Biobank participants (40-69 years), we identified predicted loss-of-function (LoF) or damaging missense (REVEL score >0.5) variants within the
Results
UNASSIGNED
A total of 45 predicted LoF or damaging missense variants were identified in the
Conclusions
UNASSIGNED
Heterozygous carriers of damaging
Identifiants
pubmed: 37645892
doi: 10.1101/2023.08.14.23294063
pmc: PMC10462211
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL105756
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH129337
Pays : United States
Déclaration de conflit d'intérêts
Conflicts of Interest: SMD receives research support from RenalytixAI and personal fees from Calico Labs, both outside the current work. MEM receives funding from Regeneron Pharmaceutical Inc. unrelated to this work. RD has received research support from AstraZeneca and Goldfinch Bio, not related to this work. BMP serves on the Steering Committee of the Yale Open Data Access Program funded by Johnson & Johnson. LMR is a consultant for the TOPMed Administrative Coordinating Center (through WeStat). The other authors have nothing to declare.